Menu
Search
|

Menu

Close
X

Precipio Inc PRPO.OQ (NASDAQ Stock Exchange Capital Market)

0.48 USD
+0.11 (+30.90%)
As of 1:30 AM IST
chart
Previous Close 0.37
Open 0.54
Volume 4,734,866
3m Avg Volume 252,563
Today’s High 0.68
Today’s Low 0.44
52 Week High 11.95
52 Week Low 0.32
Shares Outstanding (mil) 6.41
Market Capitalization (mil) 12.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
2
FY15
2
EPS (USD)
FY18
-0.473
FY17
-19.333
FY16
-9.442
FY15
-27.913
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
9.39
5.73
Price to Book (MRQ)
vs sector
0.63
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
4.38
16.84
LT Debt to Equity (MRQ)
vs sector
0.70
12.51
Return on Investment (TTM)
vs sector
-277.98
14.61
Return on Equity (TTM)
vs sector
-812.60
16.34

EXECUTIVE LEADERSHIP

Samuel Riccitelli
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Ilan Danieli
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Carl Iberger
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Douglas Sites
Vice President - Sales, Since 2018
Salary: --
Bonus: --
David Cohen
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12325 Emmet St
OMAHA   NE   68164-4243

Phone: +1203.7877888

Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.

SPONSORED STORIES